|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients显示文摘 | DABAJA B S SUKI D PRO B | 2004 | Cancer2004，101，3： | 1 |
| 2 | Results from a pivotal, open- label, phase Ⅱ study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy显示文摘 | Coiffier B Pro B Prince HM | 2012 | J Clin Oncol2012，30，6： | 1 |
| 3 | Phase Ⅱ trial ofdenileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma 显示文摘 | Dang NH Pro B Hagemeister FB | 2007 | Br J Haematol2007，136，3： | 1 |
| 4 | R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma(DLBCL)with aggressive features in patients younger than 60 years显示文摘 | Fayad L Pro B Hagemeister F | 2007 | Blood2007，110，11： | 1 |
| 5 | Platelet aggregates- genitor cell proliferation and and foam cells is mediated by in vitro 显示文摘 | Stellos K Seizer P Bigalke induced human CD34 + pro different stromal Hemost iation to macrophages cell derived factor 1 B | 2010 | Semin Thromb2010，36，2： | 1 |
| 6 | Long-term follow-up of a prospective stu dy of combined modality therapy for stage Ⅰ-Ⅱ indolent non-Hodgkin's ly mphoma显示文摘 | Seymour JF Pro B Fuller LM | 2003 | J Clin Oncol2003，21，11： | 1 |
| 7 | Long-term follow-up of a prospective study of combined modality therapy for stage Ⅰ-Ⅱ indolent non-Hodgkin's lymphoma显示文摘 | Seymour JF Pro B Fuller LM | | 0，，11： | 1 |
| 8 | Phase 2 study of gemeitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma 显示文摘 | Oki Y Pro B Fayad LE | 2008 | Cancer2008，112，4： | 1 |
| 9 | Pralatrexate Is Effective In Pa- tients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens 显示文摘 | Goy A Pro B Savage KJ | 2010 | Blood2010，116，21： | 1 |
| 10 | Phase Ⅱ study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma显示文摘 | Wang M OkiY Pro B | 2009 | J Clin Oncol2009，27，31： | 1 |
| 11 | Adenocareinoma of the small bowel: presentation, prog-nostic factors, and outcome of 217 patients显示文摘 | Dabaja BS Suki D Pro B | 2004 | Cancer2004，101，3： | 1 |
| 12 | Phase Ⅱ study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma显示文摘 | Oki Y Mclaughl P Pro B | 2005 | Cancer2005，104，4： | 1 |
| 13 | Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastie large-cell lymphoma: results of a phase II study显示文摘 | Pro B Advani R Brice P | 2012 | J Clin Oncol2012，30，18： | 1 |
| 14 | Comparison of extracts prepared from plant by-produces using different solvents and extraction time显示文摘 | LAPORNIK B PRO EK M WONDRA A G | 2005 | J Food Eng2005，71，2： | 1 |
| 15 | Comparison of extracts prepared from plant by-products using different solvents and extraction time 显示文摘 | LAPORNIK B PRO~EK M WONDRA A G | 2005 | Journal of Food Engineering2005，71，2： | 1 |
| 16 | Phase Ⅱ study of oxalplatin in patients with recurrent or refractory non-Hodgkin lymphoma显示文摘 | OKI Y MCLAUGHLIN P PRO B | 2005 | Cancer2005，104，4： | 1 |
| 17 | Effecttreatment of chronic idiopathic thrombocytopenic pur-pura :a randomised, double-blind, placebo-controlledtrial显示文摘 | BUSSEL J B PRO VAN D’SHAMSI T | 2009 | Lancet2009，373，： | 1 |
| 18 | Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy 显示文摘 | Coiffier B Pro B Prince HM | 2012 | J Chn Oncol2012，30，6： | 1 |
| 19 | Phase 2 Study of Gemcitabine in Combination With Rituximab in Patients With Recurrent or Refractory Hodgkin Lymphoma显示文摘 | Oki Y Pro B Fayad LE | 2008 | Cancer2008，112，4： | 1 |
| 20 | Thalidomide for patients with recurrent lymphoma显示文摘 | Pro B Younes A Albitar M | 2004 | Cancer2004，100，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员